Research programme: dengue vaccine - Maxygen/sanofi pasteur

Drug Profile

Research programme: dengue vaccine - Maxygen/sanofi pasteur

Alternative Names: MAXY 1500

Latest Information Update: 10 Jun 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Maxygen
  • Developer sanofi pasteur
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Dengue

Most Recent Events

  • 10 Jun 2013 Discontinued - Preclinical for Dengue in USA (unspecified route)
  • 04 Dec 2007 Maxygen's dengue vaccine programme licensed to sanofi pasteur worldwide
  • 19 Jun 2006 This vaccine is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top